Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.

C Porta; A Levy; R Hawkins; D Castellano; J Bellmunt; P Nathan; R McDermott; J Wagstaff; P Donnellan; J McCaffrey; F Vekeman; MP Neary; J Diaz; F Mehmud; MS Duh

doi:10.1002/cam4.302

Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.

C Porta, A Levy, R Hawkins, D Castellano, J Bellmunt, P Nathan, R McDermott, J Wagstaff, P Donnellan, J McCaffrey, F Vekeman, MP Neary, J Diaz, F Mehmud, MS Duh

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1517-1526
Number of pages	9
Journal	Cancer Medicine
Volume	3
Issue number	6
DOIs	https://doi.org/10.1002/cam4.302
Publication status	Published - Dec 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cam4.302

Cite this

Porta, C., Levy, A., Hawkins, R., Castellano, D., Bellmunt, J., Nathan, P., McDermott, R., Wagstaff, J., Donnellan, P., McCaffrey, J., Vekeman, F., Neary, MP., Diaz, J., Mehmud, F., & Duh, MS. (2014). Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. Cancer Medicine, 3(6), 1517-1526. https://doi.org/10.1002/cam4.302

@article{c793e0f0a9de45a294fb1ab404e73a05,

title = "Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.",

author = "C Porta and A Levy and R Hawkins and D Castellano and J Bellmunt and P Nathan and R McDermott and J Wagstaff and P Donnellan and J McCaffrey and F Vekeman and MP Neary and J Diaz and F Mehmud and MS Duh",

year = "2014",

month = dec,

doi = "10.1002/cam4.302",

language = "English",

volume = "3",

pages = "1517--1526",

journal = "Cancer Medicine",

issn = "2045-7634",

publisher = "John Wiley & Sons Ltd",

number = "6",

}

Porta, C, Levy, A, Hawkins, R, Castellano, D, Bellmunt, J, Nathan, P, McDermott, R, Wagstaff, J, Donnellan, P, McCaffrey, J, Vekeman, F, Neary, MP, Diaz, J, Mehmud, F & Duh, MS 2014, 'Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.', Cancer Medicine, vol. 3, no. 6, pp. 1517-1526. https://doi.org/10.1002/cam4.302

Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. / Porta, C; Levy, A; Hawkins, R et al.
In: Cancer Medicine, Vol. 3, No. 6, 12.2014, p. 1517-1526.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.

AU - Porta, C

AU - Levy, A

AU - Hawkins, R

AU - Castellano, D

AU - Bellmunt, J

AU - Nathan, P

AU - McDermott, R

AU - Wagstaff, J

AU - Donnellan, P

AU - McCaffrey, J

AU - Vekeman, F

AU - Neary, MP

AU - Diaz, J

AU - Mehmud, F

AU - Duh, MS

PY - 2014/12

Y1 - 2014/12

U2 - 10.1002/cam4.302

DO - 10.1002/cam4.302

M3 - Article

SN - 2045-7634

VL - 3

SP - 1517

EP - 1526

JO - Cancer Medicine

JF - Cancer Medicine

IS - 6

ER -

Porta C, Levy A, Hawkins R, Castellano D, Bellmunt J, Nathan P et al. Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. Cancer Medicine. 2014 Dec;3(6):1517-1526. doi: 10.1002/cam4.302